GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (OTCPK:NPRRF) » Definitions » EV-to-EBITDA

Nipro (NPRRF) EV-to-EBITDA : 23.86 (As of May. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nipro EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nipro's enterprise value is $5,027 Mil. Nipro's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $211 Mil. Therefore, Nipro's EV-to-EBITDA for today is 23.86.

The historical rank and industry rank for Nipro's EV-to-EBITDA or its related term are showing as below:

NPRRF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -121.56   Med: 26.07   Max: 39.18
Current: 25.54

During the past 13 years, the highest EV-to-EBITDA of Nipro was 39.18. The lowest was -121.56. And the median was 26.07.

NPRRF's EV-to-EBITDA is ranked worse than
72.11% of 484 companies
in the Medical Devices & Instruments industry
Industry Median: 16.27 vs NPRRF: 25.54

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Nipro's stock price is $8.50. Nipro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Nipro's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nipro EV-to-EBITDA Historical Data

The historical data trend for Nipro's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro EV-to-EBITDA Chart

Nipro Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.40 18.94 10.70 8.85 10.26

Nipro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.87 10.26 32.67 29.61 25.93

Competitive Comparison of Nipro's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Nipro's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nipro's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nipro's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nipro's EV-to-EBITDA falls into.



Nipro EV-to-EBITDA Calculation

Nipro's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5027.154/210.682
=23.86

Nipro's current Enterprise Value is $5,027 Mil.
Nipro's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $211 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nipro  (OTCPK:NPRRF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nipro's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.50/0.000
=N/A

Nipro's share price for today is $8.50.
Nipro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nipro EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nipro's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nipro (NPRRF) Business Description

Traded in Other Exchanges
Address
3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (NPRRF) Headlines

No Headlines